Skip to content

CROI: Risk of second virological failure has declined since 1996, but risk of death remains stable

CROI: TDM-based PI dose escalation shows modest benefit in black and Hispanic, but not Caucasian, treatment-experienced patients

CROI: Darunavir found effective and tolerable in treatment-experienced children and adolescents at 24 weeks

CROI: Could earlier ART reduce risk of death from non-AIDS related illnesses in people with HIV?

CROI: CCR5 antagonist SCH532706 shows potent activity and good tolerability in small trial

CROI: Risk of treatment interruption persists after restarting HAART

CROI: Vicriviroc appears safe and effective at higher doses in treatment-experienced patients after 48 weeks

CROI: DAD cohort finds increased risk of heart attack in people taking abacavir or ddI

CROI: Once-daily boosted atazanavir comparable to twice-daily Kaletra in treatment-naive patients, with better lipid profile